The search terms used were obesity, OSA, ASP, EDS, CPAP, glucagon-like peptide-1 (GLP-1), GLP-1 receptor (GLP-1R) agonists, liraglutide (LIRA), exenatide (EXE), semaglutide (SEMA), dulaglutide (DULA), sodium-glucose co-transporters 2 (SGLT2) inhibitors, empagliflozin (EMPA), dapagliflozin (DAPA), ertugliflozin (ERTU), canagliflozin (CANA), and luseogliflozin (LUSEO)
Common primary uses for KPV include SIBO, Ulcerative Colitis, IBD, mast cell stabilization, eczema, and psoriasis
While novel therapies, such as those derived from nanotechnology or personalized medicine, hold great potential for improving treatment outcomes, their high development costs and complexity can limit accessibility for patients
Development Stage and Evidence: advantage goes to Semaglutide